Second Sight Medical Products (NASDAQ:EYES) posted its quarterly earnings data on Monday. The medical device company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.16), Fidelity Earnings reports. Second Sight Medical Products had a negative return on equity of 183.76% and a negative net margin of 994.14%.
EYES opened at $0.97 on Tuesday. The company has a quick ratio of 1.74, a current ratio of 1.88 and a debt-to-equity ratio of 0.33. Second Sight Medical Products has a 12 month low of $0.71 and a 12 month high of $8.96. The company has a fifty day simple moving average of $1.04 and a 200 day simple moving average of $2.50. The stock has a market cap of $15.19 million, a P/E ratio of -0.41 and a beta of 2.41.
EYES has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $2.50 price objective on shares of Second Sight Medical Products in a research report on Friday, March 20th. Zacks Investment Research cut shares of Second Sight Medical Products from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, ValuEngine upgraded shares of Second Sight Medical Products from a “hold” rating to a “buy” rating in a research report on Thursday, April 9th.
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.